{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"122.1","upperLimit":"134.9","value":"128.5"},{"groupId":"OG001","lowerLimit":"116.5","upperLimit":"125.5","value":"121.02"},{"groupId":"OG002","lowerLimit":"113.8","upperLimit":"121.7","value":"117.8"},{"groupId":"OG003","lowerLimit":"109.3","upperLimit":"119.9","value":"114.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"77"}],"units":"Participants"}],"description":"The FACT-H\\&N (version 4) consists of a cancer-specific questionnaire, FACT-G, in addition to 12 H\\&N cancer-specific items (the HN subscale). FACT-G is a 27-item measure that assesses general cancer quality of life. FACT-HN total score ranges between 0 and 148. The higher the score, the better the QOL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, low risk patients are under observation.","id":"OG000","title":"Arm S (Surgery) Then Arm A (Low Risk, Observation)"},{"description":"Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, intermediate risk patients receive low-dose IMRT (50 Gy) QD five days a week for 5 weeks.","id":"OG001","title":"Arm S (Surgery) Then Arm B (Intermediate Risk, Low-dose IMRT)"},{"description":"Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, intermediate risk patients receive standard-dose IMRT (60 Gy) QD five days a week for 6 weeks.","id":"OG002","title":"Arm S (Surgery) Then Arm C (Intermediate Risk, Standard-dose IMRT)"},{"description":"Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, high risk patients then receive IMRT (66Gy) QD five days a week for 6-7 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.","id":"OG003","title":"Arm S (Surgery) Then Arm D (High Risk, IMRT, Chemotherapy)"}],"paramType":"MEAN","populationDescription":"Eligible and treated patients with FACT-HN total scores 6 months after treatment available","reportingStatus":"POSTED","timeFrame":"Assessed at 6 months after treatment","title":"Quality of Life (QOL) at 6 Months After Treatment Assessed by Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-HN) Total Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}